

Scandinavian Real Heart AB Announces Outcome of Exercise of Warrants of Series TO 3

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES.

Scandinavian Real Heart AB (publ) ("Realheart" or the "Company") today announces the outcome of the subscription period for the warrants of series TO 3 ("Warrants") issued in connection with the rights issue of units carried out by the Company during the period June 12, 2024 - July 5, 2024. In total, 31,998,400 Warrants were exercised for subscription of 159,992 shares, corresponding to a subscription rate of approximately 58 percent of the total 54,910,406 issued Warrants. Through the exercise, Realheart will receive approximately SEK 2.1 million before issue costs.

Overview of the Final Outcome

The exercise period for the Warrants ran from March 3, 2025 to March 31, 2025. The final outcome shows that 159,992 shares were subscribed for through the exercise of Warrants, corresponding to an exercise rate of approximately 58 percent. The subscription price for one share subscribed for through the exercise of the Warrants was SEK 12.98, which, in accordance with the terms of the Warrants, corresponds to 70 percent of the volume weighted average price (VWAP) of the Company's share on Nasdaq First North Growth Market during the measurement period. Through the exercise, Realheart will receive approximately SEK 2.1 million before issue costs.

Shares and Share Capital

By exercising the Warrants, the total number of shares in Realheart increases by 159,992, resulting in the total number of outstanding shares in the Company increasing from 2,153,330 to 2,313,322. The share capital of the Company increases by SEK 801,559.92 from SEK 10,788,183.30 to SEK 11,589,743.22, in accordance with the terms of the issue. For existing shareholders who have not exercised any Warrants, the dilution amounts to approximately 7 percent of the total number of shares and votes in the Company after the exercise of the Warrants.

Exercised Warrants are replaced with interim shares until registration with the Swedish Companies Registration Office, after which the interim shares are automatically converted into ordinary shares. The interim shares are expected to be converted into shares approximately two banking days after registration with the Swedish Companies Registration Office.

IMPORTANT INFORMATION

The information in this press release may not be announced, published or distributed, directly or indirectly, within or into the United States, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea, Switzerland or any other jurisdiction where such action would be unlawful, subject to legal restrictions or require measures other than those required by Swedish law. Any action in contravention of this announcement may constitute a violation of applicable securities laws. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Realheart in any jurisdiction, neither from Realheart nor from anyone else.

This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction.

This press release does not identify or purport to identify any risks (direct or indirect) that may be associated with an investment in the Company. The information contained in this press release is for the purpose of describing the background to the exercise of the Warrants only and does not purport to be complete or exhaustive. No representation is made as to the accuracy or completeness of the information contained in this announcement.

This press release does not constitute an offer or invitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an applicable exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of such securities in the United States.

In the United Kingdom, this document, and any other materials in relation to the securities referred to herein, is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (ii) high net worth persons as referred to in Article 49(2)(a) to (d) of the Order (all such persons are collectively referred to as "relevant persons"). Any investment or investment activity to which this communication relates is available in the United Kingdom only to relevant persons and will be engaged in only with relevant persons. Persons who are not relevant persons should not take any action based on this announcement or act or rely on it.

For more information, please contact:

Ina Laura Perkins, CEO

Phone: +46 (0) 70 406 49 21

E-mail: inalaura.perkins@realheart.se

Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se



PRESS RELEASE
02 April 2025 12:30:00 CEST

About Us

Scandinavian Real Heart AB (publ) is developing the first artificial heart that mimics the shape, function, and blood flow pattern of the human heart. These unique product features provide completely new opportunities to save lives and give patients a good quality of life while waiting for a heart transplant. In the future, artificial hearts may also become an alternative to transplantation for broader groups of patients with severe heart failure. Realheart® TAH (Total Artificial Heart) is now being evaluated in extensive preclinical trials ahead of a first clinical study in patients. The company's shares are traded on Nasdaq Stockholm First North Growth Market. For more information, visit www.realheart.se